Wed Jul 16 03:20:00 UTC 2025: **Anthem Biosciences IPO Closes Today, Sees Strong Demand from Retail and HNI Investors**

**Mumbai, July 16** – The initial public offering (IPO) of Anthem Biosciences Ltd., valued at ₹3,395 crore, is set to close for subscription today, July 16th, after drawing significant interest, particularly from retail and high net-worth individual (HNI) investors.

The IPO, which opened on July 14th, is entirely an offer for sale (OFS) of 5.96 crore equity shares by existing shareholders. Anthem Biosciences will not receive any proceeds from the IPO. Shares are priced at ₹570 per share.

As of the end of Day 2, the IPO was subscribed 3.48 times. The retail portion was booked 2.21 times, while the non-institutional investors’ (NII) quota saw an even stronger response, with a subscription rate of 10.26 times. Qualified institutional buyers (QIBs), however, have bid for only 0.62 times the reserved portion so far.

The grey market premium (GMP) for Anthem Biosciences has been on the rise, currently standing at ₹156. Analysts estimate a listing price of around ₹726, based on the upper price band of ₹570, suggesting a potential listing gain of 27.37%.

Several brokerages have recommended subscribing to the IPO, citing Anthem Biosciences’ strong position in the growing contract research, development, and manufacturing (CRDMO) industry and its impressive financial track record.

SBI Securities noted the company’s expansion plans, consistent profitability, and robust business pipeline, deeming the IPO “fairly priced” compared to its peers. Anand Rathi also gave a ‘Subscribe’ rating, highlighting Anthem’s focus on specialty ingredients and peptides, supported by strong client relationships and a fee-for-service model.

Rajan Shinde, research analyst at Mehta Equities, stated that the IPO offers a valuable opportunity to invest in the expanding CRDMO sector. He emphasized Anthem’s successful track record of over 8,000 completed projects and 675 clients served, along with its adoption of advanced technologies.

While acknowledging a seemingly high price-to-earnings (PE) ratio of 70x, analysts point out that it is still lower than the industry average of 80x–90x, and given Anthem’s consistent revenue growth and improving profit margins, the IPO presents a fair entry point for long-term investors.

Anthem Biosciences reported a 34.3% revenue increase in FY24, followed by a 30% increase in FY25. Net profit rose 22.9% in FY25 after a 4.6% dip in the previous year.

The company also maintains strong margins and has a pipeline of over 240 active projects, driven by its focus on innovation, green chemistry, and complex drug development.

Bidding for the IPO closes today, July 16. Share allotment is expected on July 17, and the shares are likely to be listed on the BSE and NSE on July 21. Investors interested in subscribing should do so before market hours conclude today.

Read More